Seattle Genetics is one of the many companies in the business of cancer research. Dr. Siegall is the CEO, president, and chairman of the board of Seattle Genetics and has had a passion for improving the lives of cancer patients since he began his career in biomedical studies. Since 2002, Dr.Siegall has been chief executive officer and has nearly 2 decades of history with Seattle Genetics, since he co-founded it way back in 2008. Since then, Dr.Siegall has lead Seattle Genetics to many cancer research advancements and breakthrough therapies for their cancer patients.
Dr.Siegall earned his Ph.D. in Genetics from George Washington University and has since acquired a long list of accomplishments. His career began at the Bristol-Myers Squibb Pharmaceutical Research Institute as a Senior Research Investigator. He was promoted to Principal Scientist before he became Staff Fellow and Biotechnology Fellow at the National Cancer Institute.
Under his leadership, Seattle Genetics was able to develop the first antibody-drug conjugates, including ADCETRIS, which the FDA approved in 2011. ADCETRIS is now available to cancer patients in over 60 countries. Dr.Siegall has also helped to fundraise over $1.2 billion in private as well as public funding to help advance research at Seattle Genetics. Dr.Siegall’s efforts have not gone unnoticed, as he received the University of Maryland Alumnus of the Year for Computer, Math, and Sciences in 2013. He was also named the Pacific Northwest Ernst & Young Entrepreneur of the Year.
Dr.Siegall’s enthusiasm is as strong as ever and he is continuing his pursuit of scientific achievements. He currently has 15 patents and is continuously looking for new ways to reach new achievement in medical research. Dr.Siegall has also published more than 70 scientific articles and continues to share his discoveries within the medical communities.
Clay Siegall is driven by the desire to find cures for cancer. He began his path by studying zoology at the University of Maryland and obtained a B.S. degree. He shows no signs of slowing down and is strongly committed to bettering the lives of those plagued by disease and is giving people hope for a cure.